Park Yong Eun, Lee Yoo Jin, Chang Ji Young, Song Hyun Joo, Kim Duk Hwan, Yang Young Joo, Kim Byung Chang, Lee Jae Gon, Yang Hee Chan, Choi Miyoung, Kim Seong-Eun, Myung Seung-Jae
Division of Gastroenterology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Intest Res. 2022 Oct;20(4):431-444. doi: 10.5217/ir.2021.00111. Epub 2022 Jan 5.
Many unexpected problems have resulted from the unprecedented coronavirus disease 2019 (COVID-19) pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.
2019年冠状病毒病（COVID-19）大流行引发了许多意想不到的问题。在COVID-19大流行期间，炎症性肠病（IBD）患者的最佳管理也一直是一项挑战。因此，韩国肠道疾病研究协会（KASID）制定了一份关于COVID-19大流行期间IBD管理的专家共识声明。该共识声明就IBD患者中COVID-19的风险和治疗提出了建议。该声明强调，IBD不是COVID-19的风险因素，应注意在维持除皮质类固醇外的药物治疗的情况下，避免使处于缓解状态的患者的IBD病情加重。
